Edwards Lifesciences Corporatio (EW)

Edwards Lifesciences Corporatio's Q·Score is 7.2/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for EW is $97.15, based on ratings from 27 Wall Street analysts. This is 15.7% above the current price of $83.98. Price targets are forward-looking estimates and not guarantees of future performance.

Edwards Lifesciences Corporatio (EW) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 25.0×. The consensus analyst price target of $97.15 is 16% above the current price.

Edwards Lifesciences Corporatio's next earnings report is expected on approximately July 23, 2026.

Edwards Lifesciences Corporatio has a net profit margin of 17.4%, which is solid for most industries. Its gross margin stands at 77.9%, indicating a high-margin business model.

Edwards Lifesciences Corporatio is reporting solid revenue growth of 16.7% year-over-year. Earnings are also growing at 8.2%, indicating improving profitability.

Edwards Lifesciences Corporatio has a debt-to-equity ratio of 0.07×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet.